middle.news
Paradigm Funds Final Push Towards Phase 3 Osteoarthritis Data
12:19pm on Friday 11th of September, 2026 AEST
•
Biotechnology and Pharmaceuticals
Read Story
Paradigm Funds Final Push Towards Phase 3 Osteoarthritis Data
12:19pm on Friday 11th of September, 2026 AEST
Key Points
US$2 million Tranche 4 drawdown completed
Approximately A$2.8 million added to working capital
Phase 3 trial enrolled 538 participants against an original target of 466
Approximately US$5 million remains available under the facility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE